<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03066817</url>
  </required_header>
  <id_info>
    <org_study_id>MSMB01</org_study_id>
    <nct_id>NCT03066817</nct_id>
  </id_info>
  <brief_title>Vitamin D and Bone Homeostasis in Ortho Polytrauma Patients</brief_title>
  <official_title>A Pilot Study of Role of Vitamin D in Regulation of Bone Homeostasis in Orthopaedic Polytrauma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York City Health and Hospitals Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Foundation of Orthopedic Trauma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>New York City Health and Hospitals Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although vitamin D is known to play a major role in multiple organ functions in healthy
      adults, including bone homeostasis, its role in the unique population of orthopaedic
      polytrauma patients has not been well described. The aim of this therapeutic randomized
      placebo-controlled feasibility study is to determine the effect of vitamin D supplementation
      initiated on admission on patients' 25(OH)-D level, bone turnover markers, and clinical
      outcomes in a cohort of adult orthopaedic polytrauma patients. Polytrauma patients with one
      or more orthopaedic injuries admitted to an urban Level I trauma center will be screened for
      eligibility based upon strict inclusion and exclusion criteria. Sixty patients meeting the
      criteria will be consented, enrolled and randomized in a 1:1 ratio to intervention and
      control (placebo) arm. Baseline 25(OH)-D and bone turnover marker levels will be drawn for
      all the patients on admission, and the intervention arm will receive a one-time dose of
      ergocalciferol (Vitamin D2) 400,000 IU shortly after enrollment. The labs will be repeated 7
      days after the initial draw or at discharge, whichever occurs first. Patients' daily
      immobilization status, baseline characteristics and clinical outcomes will be recorded.
      Statistical methods will be used to assess whether there is a difference in 25(OH)-D and bone
      turnover markers levels associated with the intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sixty polytrauma patients presenting to Jacobi Medical Center will be screened for
      eligibility according to strict inclusion and exclusion criteria by study personnel on
      admission. Medical history, physical examination, and laboratory findings will be collected
      and assessed to ensure that patients meet the inclusion and exclusion criteria. Eligible
      subjects will be enrolled after obtaining informed consent from either the subject or health
      care proxy if the subject is not able to participate in the decision-making process secondary
      to his injuries or mental status. As this dose of vitamin D has not been previously studied
      in pregnant subjects, female subjects will be counseled on potential pregnancy risks and will
      undergo urine pregnancy testing prior to administration of the investigational agent/placebo.
      Female patients testing positive for pregnancy will be removed from the study. Upon
      enrollment, study personnel will assign subjects a study ID and record this information in a
      password-protected data collection document.

      All enrolled subjects will have blood draws by phlebotomy or nursing staff for the
      above-mentioned bone turnover markers once consent is obtained. This will include specimen
      collection and processing for the following serum levels in both study arms: 25(OH)-D, PTH,
      collagen type I C-telopeptide, calcium, phosphorus, osteocalcin, and alkaline phosphatase.
      This initial specimen collection will occur in the interval between 0 and 72 hours of
      hospital admission.

      Collected specimen will be assigned unique identifiers corresponding to patients' study IDs
      and delivered to core labs at Jacobi Medical Center. From there, the specimen will be sent to
      an outside testing facility (Northwell Laboratories, Lake Success, NY), where specimen
      processing will occur. Normal laboratory values will be established by the outside testing
      facility according to CLIA standards.

      The study personnel will liaise with the JMC Main or Satellite Pharmacy to alert them
      regarding newly enrolled study subjects. The pharmacist will then assign patients according
      to randomization algorithm in a 1:1 ratio to intervention and control arms, with 30 patients
      in each group by the end of the study accrual. The pharmacist will then prepare and transport
      the investigational agent or placebo to the subject's location for administration by nursing
      staff.

      The intervention cohort will receive 400,000IU liquid ergocalciferol (50cc of 8000IU/cc
      Calcidol solution) via oral, NG tube, or gastrostomy route.

      The control cohort will receive 50cc of propylene glycol as placebo via oral, NG tube, or
      gastrostomy route.

      A repeat specimen collection of above-mentioned bone turnover markers will commence either at
      7 days if patient is still inpatient, or at discharge, whichever occurs first. The specimens
      obtained at that time will be treated in the same manner as the initial specimens.

      For each enrolled subject, the investigators will collect data from hospital presentation to
      discharge on standard demographics, routine laboratory results, clinical and injury
      characteristics and hospital course data (length of stay, in-hospital mortality, mobilization
      status, associated inpatient procedures and complications).
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>25(OH)-D serum level in relation to other serum markers of bone turnover</measure>
    <time_frame>1 week</time_frame>
    <description>Serum Vitamin D Level, Serum Parathyroid Hormone Level, Serum C-terminal Telopeptide Level, Serum Osteocalcin Level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>1 week</time_frame>
    <description>Patient hospital length of stay if patient leaves before hospital day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital morbidity and mortality</measure>
    <time_frame>1 week</time_frame>
    <description>Statistics regarding in-hospital morbidity and mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <condition>Polytrauma</condition>
  <condition>Orthopedic Disorder</condition>
  <arm_group>
    <arm_group_label>Vitamin D control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control cohort will receive 50cc of propylene glycol as placebo via oral, nasogastric tube, or gastrostomy route on hospital admission.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D intervention cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention cohort will receive a one-time 400,000 IU liquid ergocalciferol (50cc of Ergocalciferol 8000 IU/ML Oral Liquid [DRISDOL]) via oral, nasogastric tube, or gastrostomy route on hospital admission.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ergocalciferol 8000 IU/ML Oral Liquid [DRISDOL]</intervention_name>
    <description>50cc of ergocalciferol 8000 IU/ml will be given to participants as a one-time dose.</description>
    <arm_group_label>Vitamin D intervention cohort</arm_group_label>
    <other_name>Calcidol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propylene Glycol</intervention_name>
    <description>50cc of propylene glycole will be given to participants as one-time dose, used as placebo</description>
    <arm_group_label>Vitamin D control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females age 18-65 years

          2. One or more orthopaedic injuries on admission

          3. Admission injury severity score (ISS)â‰¥16

          4. Anticipated stay in hospital of more than 7 days

        Exclusion Criteria:

          1. Pregnancy (if patient becomes pregnant during the study, she will be removed from the
             study)

          2. End stage kidney disease

          3. Patients on furosemide, thiazide, or corticosteroid therapy

          4. Patients with chronic liver disease

          5. Patients with recent history of vitamin D supplementation more than 5000 IU/day

          6. Patients actively undergoing chemo- or immunotherapy

          7. Patients with hematologic and solid malignancies

          8. Patients receiving treatment for osteoporosis

          9. Patients with &quot;nothing per mouth&quot; status secondary to any preceding procedures
             involving their GI system (e.g. patients with colectomy performed on this admission
             secondary to gunshot wound to abdomen)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Milan Sen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center / Jacobi Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jacobi Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2017</study_first_submitted>
  <study_first_submitted_qc>February 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2017</study_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>Deficiency</keyword>
  <keyword>Insufficiency</keyword>
  <keyword>Bone turnover</keyword>
  <keyword>Bone healing</keyword>
  <keyword>Polytrauma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Multiple Trauma</mesh_term>
    <mesh_term>Musculoskeletal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data are not planned to be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

